News

Impax Pharmaceuticals will utilize its 66 neurology-focused sales force to promote Pristiq (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor as a treatment for adult patients with major depressive disorder. As

The cooperative R&D agreement with Maxim Biotech will initially focus on the development of a family of life science research reagent tool kits which can be used to

The company has also announced that William Rueckert has resigned from its board, and has accepted a position on the board of the company’s 72% shareholder, Novogen. Ms

Previously, Dr Emerson has served as director of computer resources at KPMG in its New York executive office; vice president of technology at Pansophic Systems; president of RTI

The acquired business includes tests sold within Inverness’s focus areas of infectious disease, cardiology, drugs of abuse and women’s health. In March 2006, Inverness acquired Acon’s rapid diagnostics

Allos Therapeutics, a biopharmaceutical company, has reported that the European Medicines Agency, with a positive opinion of the Committee for Orphan Medicinal Products, has granted orphan medicinal product

The two centers generate approximately $5.6 million in annual revenues. One center is exclusively magnetic resonance imaging (MRI) while the other is a multi-modality facility. The acquisition is

BioNanomatrix, a developer of nanoscale platforms for biomedical research, molecular diagnostics and personalized medicine, has received a Phase II grant from the National Human Genome Research Institute of

Under the terms of the agreement, Lipoxen will provide Glide Pharma with SuliXen which Glide Pharma will then incorporate into its proprietary Glide SDI, needle-free, drug delivery technology